They further suggested that gamabufotalin could be a potent sensitizer of temozolomide, one of the most used clinical drugs for glioblastoma, by triggering a negative feedback loop involving the sodium pump α3 subunit (ATP1A3) and aquaporin 4 to activate p38 MAPK in glioblastoma cells [41]. Here, ATP1A3 is linked to glioblastoma.